What's the Next Stop for Inovio: $5 or $15?
With its shares up 500% over the past two years, is Inovio poised for more upside or a 50% haircut?
Could These Tiny Biotech Stocks Double in 2015?
Ophthotech Corporation, Achillion Pharmaceuticals, and Portola Pharmaceuticals all have catalysts that could lift shares in 2015.
3 Value Stocks Near 52-Week Lows Worth Buying
These three value stocks have been beaten up recently, but there's a chance they may not stay near their 52-week lows for much longer.
3 Biotech Stocks I Don't Want for Christmas
I’d prefer coal in my stocking to these three troubled biotech stocks.
The Most Disappointing Clinical Failures in 2014
Three Motley Fool contributors tell us what they think were the biggest drug trial failures this year.
Why ImmunoGen Inc. Stock Was Throttled
ImmunoGen shares lose half their value following an update on a key breast cancer drug trial. Find out whether today's swoon could mark a buying opportunity.
3 Beaten Down Stocks Ready to Bounce Back
Not all stocks had a great 2014. Here are three stocks that could be ready for a comeback.
This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year
A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.
This is Incredibly Good News for Breast Cancer Survivors
A recently released study from Canada shines light on the advancements made in treating breast cancer over the past two decades.
Why Inovio Pharmaceuticals Inc. Stock Plunged 15% in November
Inovio Pharmaceuticals stock dips by double-digits in November after the company witnesses a key licensing deal with a major pharmaceutical company come to an end.